<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090111</url>
  </required_header>
  <id_info>
    <org_study_id>ALG-055009-301</org_study_id>
    <nct_id>NCT05090111</nct_id>
  </id_info>
  <brief_title>A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aligos Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aligos Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Study of ALG-055009 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics&#xD;
      and Pharmacodynamics of Single and Multiple Doses in Healthy Volunteers and Subjects with&#xD;
      Hyperlipidemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 14 days for Part 1</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 28 days for Part 2</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 35 days for Part 3</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Predose (between -0.25 hours and 0 hours) up to 35 Days</time_frame>
    <description>Pharmacokinetic parameters of ALG-055009 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve [AUC]</measure>
    <time_frame>Predose (between -0.25 hours and 0 hours) up to 35 Days</time_frame>
    <description>Pharmacokinetic parameters of ALG-055009 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration [Tmax]</measure>
    <time_frame>Predose (between -0.25 hours and 0 hours) up to 35 Days</time_frame>
    <description>Pharmacokinetic parameters of ALG-055009 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life [t1/2]</measure>
    <time_frame>Predose (between -0.25 hours and 0 hours) up to 35 Days</time_frame>
    <description>Pharmacokinetic parameters of ALG-055009 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration [Cmin]</measure>
    <time_frame>Predose (between -0.25 hours and 0 hours) up to 35 Days</time_frame>
    <description>Pharmacokinetic parameters of ALG-055009 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid / lipoprotein levels from baseline through Day 28 in Multiple Dose in Subjects with Mild Hyperlipidemia</measure>
    <time_frame>Screening, Day -1 to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>ALG-055009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral dose(s) of placebo in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALG-055009</intervention_name>
    <description>Single or multiple doses of ALG-055009</description>
    <arm_group_label>ALG-055009</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single or multiple doses of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Healthy Subjects:&#xD;
&#xD;
          1. Male and Female between 18 and 55 years old&#xD;
&#xD;
          2. BMI 18.0 to 32.0 kg/m^2&#xD;
&#xD;
        Inclusion Criteria for Subjects with Mild Hyperlipidemia:&#xD;
&#xD;
          1. Male and Female between 18 and 65 years old&#xD;
&#xD;
          2. BMI 18.0 to 35.0 kg/m^2&#xD;
&#xD;
          3. Subject must be on a stable diet for the 3 months prior to screening with a fasting&#xD;
             LDL-C level &gt;110 mg/dL at screening&#xD;
&#xD;
        Exclusion Criteria for All Subjects:&#xD;
&#xD;
          1. Subjects with any current or previous illness that, in the opinion of the&#xD;
             Investigator, might confound the results of the study or pose an additional risk in&#xD;
             administering study drug to the subject or that could prevent, limit, or confound the&#xD;
             protocol specified assessments or study results' interpretation&#xD;
&#xD;
          2. Subjects with Hepatitis A, B, C or HIV-1/HIV-2 infection or acute infections such as&#xD;
             SARS- CoV-2 infection&#xD;
&#xD;
          3. Subjects with renal dysfunction (e.g., estimated creatinine clearance &lt;90 mL/min/1.73&#xD;
             m^2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             [CKD-EPI] formula)&#xD;
&#xD;
          4. Subjects with history of thyroid disorder or abnormal thyroid function tests at&#xD;
             screening or known sensitivity to thyroid medications&#xD;
&#xD;
          5. Subjects receiving, or urgently requiring, any lipid lowering therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Melissa Richardson</last_name>
      <phone>02 99 59 91 91</phone>
      <email>melissa.richardson@biotrial.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

